HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- ‘Powerful clues’ show tumor biology contributes to racial disparities in mortality
-
- The contagiousness of burnout Mark Hyde, PhD, PA-C
- AACR president to lead City of Hope National Medical Center
- ASCO to honor UCLA oncologist for advancement of cancer survivorship
- ASH presents Scholar Awards
- Atezolizumab plus bevacizumab and chemotherapy prolongs PFS in non-small cell lung cancer
- AACR president to lead City of Hope National Medical Center
- AACR president to lead City of Hope National Medical Center
- FDA approves Cabometyx for untreated advanced renal cell carcinoma
-
- Hemlibra prophylaxis every 4 weeks controls bleeds in hemophilia A
- Ibrutinib plus rituximab extends PFS in Waldenström’s macroglobulinemia
- Intraoperative molecular imaging helps identify more cancerous lung nodules
- Online tumor boards help ensure underserved patients in developing countries treated ‘properly, cohesively’
- Q&A: Why health care remains a target to cyberattacks like WannaCry
- Fire and fury in cancer cells and politics Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA approves Gazyva for treatment-naive advanced follicular lymphoma
- FDA approves Sutent to reduce risk for recurrent kidney cancer
-
- FDA clears new test to aid in identifying hereditary colon cancer
- FDA grants CAR T-cell therapy bb2121 breakthrough therapy designation for multiple myeloma
- Aging-related disease risks high among thyroid cancer survivors
- Antibody drug conjugate shows promise for metastatic colorectal cancer
- Cancer drug costs increase over time despite increased competition
- Depression linked to premature health decline in cancer caregivers
- Multiple immunotherapies fail to show durable survival on ASCO value framework
- Platinum-based chemotherapy should not be delayed for relapsed ovarian cancer
-
- Reflux linked to head and neck cancers in elderly
- Replacing saturated fats with polyunsaturated fats reduces lung cancer risk
- ASH acknowledges three Choosing Wisely Champions
- Autoimmune conditions, infections common among diffuse large B-cell lymphoma survivors
- Caplacizumab induces response in acquired thrombotic thrombocytopenic purpura
- CAR T-cell therapy bb2121 shows promising efficacy for multiple myeloma
- CDK4/6 inhibitors may benefit older patients with metastatic breast cancer
- Durvalumab plus tremelimumab shows modest activity for advanced sarcoma
-
- Edoxaban noninferior to standard VTE therapy for patients with cancer
- Home stem cell transplantation could lower infections, costs
- Ixabepilone remains inferior to paclitaxel in metastatic disease
- Lurbinectedin shows activity in pretreated Ewing sarcoma
- Lymph node surgery increases arm morbidity in younger women with breast cancer
- Minimal residual disease a ‘powerful’ predictor for AML relapse, survival
- Mogamulizumab superior to vorinostat for cutaneous T-cell lymphoma
- Need for transfusions delays hospice care for patients with leukemia
-
- Novel dual mTOR inhibitor fails to extend PFS for ER-positive breast cancer
- Older adults underrepresented in clinical trials for blood cancers
- Ponatinib appears safe, effective for older patients with Philadelphia chromosome-positive ALL
- Preoperative endocrine therapy improves outcomes for certain women with DCIS
- Researchers quantify presence of immunotherapy biomarkers in breast cancer
- Risk score predicts recurrence risk in women with DCIS
- Sacituzumab govitecan shows promise for advanced triple-negative breast cancer
- TAS-115 shows preliminary antitumor activity for osteosarcoma
-
- Transplant-associated thrombotic microangiopathy may be ‘final pathway’ of other disorders
- Surgical margins predict survival in primary pleomorphic liposarcoma
- Short-term adjuvant therapy fails to improve DFS in HER-2-positive breast cancer
- Should different prostate cancer screening guidelines exist for black men?